CA
Speaker:
Daniel Gil, PhD of Siege Pharmaceuticals
Title:
Rational Drug Design to Optimize Selectivity
Abstract:
The lecture will explore approaches to discovering selective small molecule drugs. Selective action can be achieved on the basis of differentialaffinity, substrate specificity, levels of activation, and pharmacokinetics. Two case studies will be presented in which older non-selective drugs areused as starting points for new discovery. The discovery of new muscarinic receptor therapeutics to treat Alzheimer’s disease using a structurebased strategy will be reviewed. In the second case study, the discovery by UC Irvine researchers of constrained sphingosine analogs to treat cancertherapeutics will be reviewed.
Register here!